Harvard Bioscience (HBIO) Return on Capital Employed (2011 - 2026)
Harvard Bioscience (HBIO) reported Return on Capital Employed of 66.25% for Q1 2026, up 17091.0% year-over-year from N/an in Q1 2025, and up 416.05% on a QoQ basis from 20.96% in Q4 2025.
Harvard Bioscience (HBIO) has 16 years of Return on Capital Employed data on file, last reported at 66.25% in Q1 2026.
- Quarterly Return on Capital Employed rose 17091.0% year-over-year to 66.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 66.25% (up 17091.0% YoY) and the FY2025 annual result came in at 14.7%, down 1152.0% from the prior year.
- Return on Capital Employed advanced to 66.25% in Q1 2026 per HBIO's latest filing, from 20.96% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 66.25% in Q1 2026 and bottomed at 196.36% in Q2 2025.
- The 5-year median for Return on Capital Employed is 3.31% (2022), against an average of 27.21%.
- The widest annual swing landed in 2025, when Return on Capital Employed plunged 18951 bps; it then surged 17091 bps in 2026.
- Tracing HBIO's Return on Capital Employed over 5 years: stood at 1.57% in 2022, then surged by 69 bps to 0.48% in 2023, then sank by 591 bps to 3.31% in 2024, then plunged by 533 bps to 20.96% in 2025, then soared by 416 bps to 66.25% in 2026.
- Per Business Quant, the three latest HBIO Return on Capital Employed figures stand at 66.25% (Q1 2026), 20.96% (Q4 2025), and 188.74% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 156.17 Bn | 151.78 Bn | 1.83 Bn | 17.54% |
| 2 | Becton Dickinson | 41.51 Bn | 40.49 Bn | 2.15 Bn | 5.02% |
| 3 | Resmed | 30.43 Bn | 28.77 Bn | 890.98 Mn | 25.95% |
| 4 | West Pharmaceutical Services | 22.78 Bn | 22.26 Bn | 296.40 Mn | 18.63% |
| 5 | Solventum | 13.39 Bn | 13.39 Bn | 1.10 Bn | 19.44% |
| 6 | Cooper Companies | 12.33 Bn | 12.20 Bn | 695.20 Mn | 6.60% |
| 7 | Align Technology | 11.65 Bn | 10.59 Bn | 736.59 Mn | 12.74% |
| 8 | Baxter International | 9.81 Bn | 7.77 Bn | 891.00 Mn | 13.02% |
| 9 | Aptargroup | 7.39 Bn | 7.19 Bn | 351.91 Mn | 12.04% |
| 10 | Harvard Bioscience | 25.38 Mn | 18.29 Mn | 12.24 Mn | 66.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.25% |
| Dec 31, 2025 | -20.96% |
| Sep 30, 2025 | -188.74% |
| Jun 30, 2025 | -196.36% |
| Mar 31, 2025 | -104.66% |
| Dec 31, 2024 | -3.31% |
| Sep 30, 2024 | -7.80% |
| Jun 30, 2024 | -6.85% |
| Mar 31, 2024 | -4.17% |
| Dec 31, 2023 | -0.48% |
| Sep 30, 2023 | 5.26% |
| Jun 30, 2023 | 2.75% |
| Mar 31, 2023 | 5.34% |
| Dec 31, 2022 | -1.57% |
| Sep 30, 2022 | -3.68% |
| Jun 30, 2022 | -0.35% |
| Mar 31, 2022 | -3.31% |
| Dec 31, 2021 | 1.56% |
| Sep 30, 2021 | 1.05% |
| Jun 30, 2021 | 0.78% |
| Mar 31, 2021 | 1.13% |
| Dec 31, 2020 | -1.16% |
| Sep 30, 2020 | -0.70% |
| Jun 30, 2020 | -1.87% |
| Mar 31, 2020 | -2.03% |
| Dec 31, 2019 | 0.27% |
| Sep 30, 2019 | 0.34% |
| Jun 30, 2019 | 1.85% |
| Mar 31, 2019 | 1.46% |
| Dec 31, 2018 | 0.70% |
| Sep 30, 2018 | -0.26% |
| Jun 30, 2018 | -1.14% |
| Mar 31, 2018 | -1.32% |
| Dec 31, 2017 | -0.66% |
| Sep 30, 2017 | -2.22% |
| Jun 30, 2017 | -2.69% |
| Mar 31, 2017 | -3.34% |
| Dec 31, 2016 | -3.14% |
| Sep 30, 2016 | -1.78% |
| Jun 30, 2016 | -1.70% |
| Mar 31, 2016 | -0.76% |
| Dec 31, 2015 | -1.59% |
| Sep 30, 2015 | 0.25% |
| Jun 30, 2015 | 2.17% |
| Mar 31, 2015 | 3.59% |
| Dec 31, 2014 | 5.61% |
| Sep 30, 2014 | 2.93% |
| Jun 30, 2014 | 2.11% |
| Mar 31, 2014 | 1.29% |
| Dec 31, 2013 | 1.22% |
| Sep 30, 2013 | 3.46% |
| Jun 30, 2013 | 4.21% |
| Mar 31, 2013 | 5.85% |
| Dec 31, 2012 | 6.41% |
| Sep 30, 2012 | 5.87% |
| Jun 30, 2012 | 5.09% |
| Mar 31, 2012 | 5.23% |
| Dec 31, 2011 | 5.18% |
| Sep 30, 2011 | 6.47% |